


Disclaimer

- The information contained in this confidential document ("Presentation") has been prepared by Grape King Bio (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers gives, has given or has authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision or supplement thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers takes any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness or injury of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation or the information.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved by the Company to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, general economic, market or business conditions and other unforeseen events. Prospective Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those is not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.

2





1.Grape King Taiwan NT\$ 175 m (+32% YoY)


Thanks to strong sales of our own brand products as well as higher ODM revenues.

2.Pro-Partner NT\$ 1,814 m (-2% YoY)

Members activities continue to normalize post pandemic while new products launched in 3Q20 are well-received by members.

3.Grape King Shanghai NT\$ 178 m (+35% YoY)

China consumption recovery has been slowerthan-expected amid a low base from last year. Good order build ahead of Double 11 shopping festival.



9M19 REVENUE 9M20 REVENUE 1.Grape King Taiwan 10% 6% 9% 7% NT\$ 484 m (+28% YoY) NTS Thanks to strong sales of our own brand NTS 6.5 bn products, with equally strong momentum 6.4 bn coming from physical and e-commerce channels. 2.Pro-Partner NT\$ 5,381 m (-2% YoY) **9M20 NET PROFIT 9M19 NET PROFIT** Members activities were mostly restricted in 1H20 but began to recover in 2H20. 9% 17% 20% **3.Grape King Shanghai** NT\$ NT\$ 851 m NT\$ 561 m (-13% YoY) 881 m 1H20 shipments were mostly affected the pandemic. While China consumption recovery post pandemic was slower-than-expected. Grape King Taiwan Pro-Partner Grape King Shanghai Grape King Taiwan Pro-Partner Grape King Shanghai

" Revenue Breakdown (9M20 v.s. 9M19)

"	3Q20	Income	Statement
---	------	--------	-----------

(NT\$m)	3Q20	3Q19	diff	ΥοΥ	2Q20	diff	QoQ	9M20	9M19	diff	YoY
Net Sales	2,168	2,112	56	2.7%	2,248	(80)	-3.6%	6,425	6,526	(101)	-1.5%
COGS	390	354	36	10.2%	428	(37)	-8.7%	1,152	1,187	(35)	-3.0%
Gross Profit	1,778	1,757	20	1.1%	1,821	(43)	-2.4%	5,273	5,339	(66)	-1.2%
Operating Expenses	(1,215)	(1,201)	(15)	1.2%	(1,310)	94	-7.2%	(3,733)	(3,755)	22	-0.6%
Selling	(1,008)	(1,012)	4	-0.4%	(1,122)	114	-10.2%	(3,164)	(3,227)	63	-2.0%
Administrative	(141)	(135)	(6)	4.2%	(125)	(15)	12.3%	(388)	(393)	5	-1.4%
R&D	(67)	(54)	(13)	24.8%	(62)	(5)	7.7%	(180)	(134)	(46)	34.5%
Operating Profit	562	556	6	1.0%	511	51	10.0%	1,541	1,584	(43)	-2.7%
Net Non-Op gain/(loss)	18	31	(12)	-40.1%	10	9	92.1%	55	76	(21)	-27.6%
Profit before Tax	581	587	(6)	-1.1%	520	61	11.7%	1,595	1,660	(64)	-3.9%
Income Tax	(118)	(117)	(1)	0.7%	(107)	(12)	10.8%	(324)	(344)	20	-5.8%
Minorities	(159)	(166)	7	-4.1%	(129)	(30)	23.6%	(421)	(435)	15	-3.4%
Net Income	304	304	(0)	-0.1%	285	19	6.6%	851	881	(30)	-3.4%
Basic EPS (NT\$)	2.23	2.24	(0.01)	-0.4%	2.09	0.14	6.7%	6.25	6.49	(0.24)	-3.7%
Fully diluted EPS (NT\$)	2.22	2.23	(0.01)	-0.4%	2.09	0.13	6.2%	6.23	6.46	(0.23)	-3.6%
Margins											
Gross margin	82.0%	83.2%	-1.2%		81.0%	1.0%		82.1%	81.8%	0.3%	
Operating expenses ratio	56.1%	56.9%	-0.8%		58.3%	-2.2%		58.1%	57.5%	0.6%	
Operating margin	25.9%	26.4%	-0.4%		22.7%	3.2%		24.0%	24.3%	-0.3%	
Pretax margin	26.8%	27.8%	-1.0%		23.1%	3.7%		24.8%	25.4%	-0.6%	
Net margin	14.0%	14.4%	-0.4%		12.7%	1.3%		13.2%	13.5%	-0.3%	

Galance Sheet

(NT\$ m)	3Q20	3Q19	diff	YoY	2019	Diff (v.s. 3Q20)
Total Assets	11,991	10,531	1,460	13.9%	11,359	632
Cash	1,671	1,186	485	40.9%	2,146	(475)
AR & NR	244	279	(35)	-12.5%	202	42
Inventories	720	584	136	23.3%	546	174
Fixed Assets	7,343	6,458	885	13.7%	6,454	889
Total Liabilities	4,659	3,674	985	26.8%	3,888	771
AP & NP	239	215	24	11.2%	223	16
Total Borrowing	2,034	1,349	685	50.8%	1,177	857
Total Equity	7,332	6,857	475	6.9%	7,471	(139)
Ratios						
A/R Turnover Days	11.0	8.8			7.3	
Inventory Turnover Days	152.8	134.3			119.3	
A/P Turnover Days	53.2	64.8			52.2	
Cash Conversion Days	110.6	78.3			74.4	
ROE (%)	19.0	21.2			22.0	
ROA (%)	10.1	11.6			11.9	
Net debt (cash)/Equity %	4.9	2.4			-13.0	

6

Gash Flow Statement

(NT\$ m)	3Q20	3Q19	diff	YoY	9M20	9M19	diff	ΥοΥ
Cash Flow From Operations	357	295	62	21%	1,300	965	335	35%
Capex	(88)	(173)	85	-49%	(1,165)	(573)	(593)	103%
Cash Flow From Investing	(96)	(232)	136	-59%	(1,183)	(633)	(550)	87%
Net increase (decrease) in short-term borrowing	600	150	450	300%	(450)	250	(700)	-280%
Net increase (decrease) in long-term borrowing	238	593	(356)	-60%	680	607	73	12%
Cash Flow From Financing	(20)	(114)	94	-83%	(592)	(1,183)	592	-50%
Cash at the End	1,671	1,186	485	41%	1671	1,186	485	41%
Free Cash Flow	269	122	147	121%	135	392	(257)	-66%

To become a global leading health and wellness company that promotes a healthier living and a more sustainable future

Our Goal



Gur Growth Strategies

n2

03

Key Objectives

Grape King Taiwan

- Market share gain
- Expanding through new adjacencies
- Accelerate overseas ODM & raw materials businesses

Pro-Partner

- Unlock growth ceiling
- Improving demand forecast, sales visibility, and products time to market


Grape King Shanghai

- Clients diversification
- Prepping for the probiotics boom

Levers

- Market share gain through products upgrade and deeper channels penetration
- Business expansion through penetrating new product categories
- Continue to promote Grape King's raw material and R&D capabilities in probiotics and medicinal mushrooms.
- Accelerate new product launches from only 1-2 new products to 3-5 products per year.
- Focus on growing younger members.
- Duplicate Taiwan success in new geographies
- Cultivate 10 new customers with the potential of each contributing Rmb 10mn sales per annum
- Develop non-direct/WeChat customers
- Capture more business opportunities through local strategic partnerships and alliances

Sustainable topline and bottomline growth



Growing on Giant's Shoulder







Investment Highlights

We are

industry leader





Strong R&D capabilities

We are a leading health food manufacturer in Greater China, specializing in probiotics, mushroom and other herbal-based supplements. We command No. 1 position in probiotics and medicinal mushrooms supplements with 31% and 45% market share, respectively in 2019.


✓ We operate the second largest direct-selling company – Pro-Partner in Taiwan (2019 market share: 8.3%).

- We are one of the few health food companies in Taiwan that possess the capability to produce our own raw materials, manufacture products and distribute through own brands and channels.
- Our expertise in raw materials allow us to develop health supplements serving different benefits.
 Therefore, many of our products are TFDA approved for different health benefits.
- We are also a frequent winner of major international conventions/competitions in respect to new product design/concept.



Solid growth with sustainable payout ratio

- ✓ We have delivered a solid earnings during 2008-2019 (CAGR of 21%/average ROE 20%).
- ✓ We have maintained more than 60% dividend payout in the past five years.
- ✓ On the back of a growing health and wellness market in Asia, we strive to deliver double digit topline growth through different growth catalysts from our individual business unit.



Company Overview : Three core business units

1. Grape King Taiwan (Parent Co) Taiwan own brand & global OEM & ODM

Locus of all key ingredient design, formulation, and production for the whole Group.


2. Pro-Partner (60%-own) Taiwan direct selling distribution

A differentiated distribution channel with products sold through direct-selling by members under the Pro-Partner brand.




3. Grape King Shanghai (100%-own) China OEM & ODM

Our manufacturing in China that focuses on OEM and ODM for domestic and global health food companies.











Competitive Strengths - State-of-the-Art Production Facilities




1. Grape King Taiwan

"



Taiwan - Grape King Brand Sales Channels





Energy drinks that restore energy and provides necessary vitamins

Metabolism promotion and digestion/defecation improvement



Improves digestion and defecation

Liver protection and hangover prevention and alleviation

2. Pro-Partner



"

Pro-Partner Overview

4 key numbers of Pro-Partner

- Largest local direct selling company in Taiwan based on revenue.
- One of the fastest growing direct selling companies in Taiwan (17% sales CAGR from 2008 to 2019)


 Second largest overall direct selling company in Taiwan. (2019 market share: 8.3%)

28

Smallest product range – 28 Health and Beauty products among the top 5

• No. 49 in the worldwide direct selling company rankings for 2018

(Source: 2019 DSN Global 100- based on 2018 revenues)





Bai Yi Jie (Toothpaste)

貝益潔

满效牙商

N.M.M.公 动波 木肥却Xylital 東化納

Grape King's Lactobacillus pentosus GK4

- → Inhibit 13 kinds of oral bacteria & Prevent cavities
- Xylitol → Anti-plaque
- Sodium fluoride
 → Prevent enamel erosion
- Mint → Sooth teeth

Hi Spray (Oral Spray)

• Grape King's Lactobacillus pentosus GK4

14: Spray Meter

→ Inhibit 13 kinds of oral bacteria & Prevent cavities

Life Spray ARAR


- Sorbitol
 - → Anti-plaque
- Thyme → Freshen breath
- Mint
 - \rightarrow Sooth teeth

How is Pro-Partner different from other direct selling companies?

Products purchase	Products' uniqueness	Support	Training	Compensation
 ✓ No minimum purchase requirement. ✓ No inventory pressure. (Members buy products directly from the company) 	 ✓ Higher entry barrier for Products (bio- researched and engineered). ✓ Symbol of national certifications. ✓ Products are mostly manufactured in- house rather than outsourced. 	✓ Managed by Grape King, a well-respected health food company in Taiwan, so we can offer dedicated customer service and support.	 ✓ All the trainings and venues are held by the company, so we can have consistent training quality. ✓ All the trainings are free to members. 	 ✓ Transparent compensation structure. ✓ All purchases can be accumulated. ✓ All compensation are paid to sales contribution and directly to the members by the company.

How is Pro-Partner different from other direct selling companies?

Nearly 80% of Pro-Partner's sales are contributed by old members



More than 75% 2015 2016 2017 2018 2019 Healthy membership growth

The growth rate of our executive distributors are similar to the growth rate of our members in the past years. This implies that our members are proportionally promoted each year based on their contribution to the group.



3. Grape King Shanghai



"

Grape King Shanghai Overview


- Established in 1993, Grape King Shanghai was initially targeted as the production base for Grape King's own brand products in China.
- A change in strategy steered by the new management to an OEM/ODM model has reversed several years of losses and turned the operation profitable.
- We see tremendous growth potential for Grape King Shanghai as it continues to acquire more ODM clients locally in China.



*In 2019, the overall demand was impacted by China government' s tightening on direct-selling and healthcare industry.












*Our Specialist Fermentation & Manufacturing Site (Zhongli plant) will relocated to Pinzhen Industrial Zone due to city development plan, expansion for PKL and different forms production line. The new plant construction is schedule to begin in the second half of 2020 with production expected to start in 2023. The relocation won't impact our operating and we expect that once the new facility is fully completed and 100% utilized, it is able to contribute additional NT\$10bn in revenue for Grape King.






Financial Highlights

Historical revenue vs. operating profit




Historical EPS vs. ROCE






Note: The drop in gross margin is due to higher contribution from Shanghai Grape King with lower gross margin from ODM, but operating margin is around the same.



Notes: The payout ratio declined in the past three years due to capacity expansion in Taiwan and Shanghai.

Revenue Breakdown (2019 v.s. 2018)



1.Grape King Taiwan NT\$ 538 m (+33% YoY)


Thanks to successful marketing from our online distribution channels. Also, our overseas ODM shipments increased made contributions.

2.Pro-Partner NT\$ 7,791 m (+5% YoY)

Sales momentum further improved on the back of membership growth and new product launches.

3.Grape King Shanghai NT\$ 910 m (-34% YoY)

The overall demand was still impacted by government's tightening on direct-selling industry. However, the decline in 4Q19 has significantly narrowed on a QoQ basis.



" Five-Year Income Statement

(NT\$ m)	2015	2016	2017	2018	2019	9M20	YoY (%)					
							2015	2016	2017	2018	2019	9M20
Revenue	7,248	9,185	9,388	9,183	9,239	6,425	15.4	26.7	2.2	(2.2)	0.6	(1.5)
Gross Profit	6,385	7,919	7,865	7,329	7,566	5,273	14.8	24.0	(0.7)	(6.8)	3.2	(1.2)
Operating Expenses	(4,573)	(5,685)	(5,610)	(4,979)	(5,231)	(3,733)	15.4	24.3	(1.3)	(11.2)	5.0	(0.6)
Operating Profit	1,812	2,234	2,254	2,350	2,335	1,541	13.3	23.3	0.9	4.2	(0.6)	(2.7)
Non Operating Income/(Loss)	70	78	151	77	105	55	(21.5)	11.8	92.6	(49.2)	36.8	(27.6)
Pretax Income	1,883	2,312	2,405	2,427	2,440	1,595	11.4	22.8	4.0	0.9	0.6	(3.9)
Tax Expenses	(336)	(426)	(471)	(537)	(502)	(324)	10.9	26.8	10.6	14.0	(6.5)	(5.8)
Minority interest	(495)	(590)	(583)	(595)	(630)	(421)	11.5	19.2	(1.3)	2.1	5.9	(3.4)
Net Income to Parent	1,052	1,297	1,352	1,295	1,309	851	11.6	23.3	4.3	(4.2)	1.1	(3.4)
Basic EPS (NT\$)	8.07	9.82	10.03	9.57	9.63	6.25	11.5	21.7	2.1	(4.6)	0.6	(3.7)
Key Financial Ratios (%)												
Gross Margin	88.1	86.2	83.8	79.8	81.9	82.1						
Operating Expense Ratio	63.1	61.9	59.8	54.2	56.6	58.1						
Operating Margin	25.0	24.3	24.0	25.6	25.3	24.0						
Effect Tax Rate	17.8	18.4	19.6	22.1	20.6	20.3						
Net Margin	14.5	14.1	14.4	14.1	14.2	13.2						

" Five-Year Balance Sheet

(NT\$ m)	2015	2016	2017	2018	2019	9M20	YoY (%)					
	2015						2015	2016	2017	2018	2019	9M20
Total Assets	8,612	9,550	9,892	10,648	11,359	11,991	60.4	10.9	3.6	7.6	6.7	13.9
Cash	1,433	1,899	1,920	2,050	2,146	1,671	4.3	32.6	1.1	6.8	4.7	40.9
AR & NR	97	204	160	171	202	244	(1.9)	111.6	(21.5)	6.8	18.0	(12.4)
Inventories	359	435	492	563	546	720	34.0	21.0	13.1	14.4	(2.9)	23.3
Fixed Assets	5,597	6,084	6,355	5,927	6,454	7,343	170.6	8.7	4.5	(6.7)	8.9	13.7
Total Liabilities	4,393	3,767	3,564	3,715	3,888	4,659	165.9	(14.3)	(5.4)	4.2	4.7	26.8
AP & NP	153	198	323	262	223	239	19.2	29.6	63.2	(18.9)	(15.1)	11.0
Total Borrowing	2,439	1,206	1,022	1,119	1,177	2,034	-	(50.6)	(15.2)	9.5	5.2	50.7
Total Equity	4,220	5,783	6,328	6,933	7,471	7,332	13.5	37.1	9.4	9.6	7.8	6.9
Key Financial Ratios (%)												
A/R Turnover Days	4.8	5.9	7.0	6.5	7.3	11.0						
Inventory Turnover Days	131.0	113.0	109.5	102.4	119.3	152.8						
A/P Turnover Days	58.6	49.9	61.6	56.8	52.2	53.2						
Cash Conversion Days	77.2	69.0	54.9	52.1	74.4	110.6						
ROE (%)	32.1	31.3	27.0	23.7	22.0	19.0						
ROA (%)	15.0	14.3	13.9	12.6	11.9	10.1						
Net debt (cash)/Equity %	23.9	(12.0)	(14.2)	(13.4)	(13.0)	4.9						

45

Dividend Payout and Capex

(NT\$ m)	2014	2015	2016	2017	2018	2019
Net profit	942	1,052	1,297	1,352	1,295	1,309
Cash dividend	690	730	862	903	883	884
DPS (NT\$)	5.3	5.6	6.4	6.7	6.5	6.5
Payout ratio	73.2%	69.4%	65.2%	66.6%	67.9%	67.4%
Cash yield	2.4%	2.6%	3.2%	2.9%	3.0%	3.3%
Сарех	187	2,635	736	772	1,116	630

Notes:

1. The big spike in capex in 2015-2017 is largely due to the investment of 1) Pro-Partner's new headquarter building, 2) the new factory and tourist factory in Pingzhen (Grape King Headquarter), 3) the new factory in Longtan (Grape King Bio-Tech Research Institute), and 4) additional production lines for Grape King Shanghai.

2. The capex for 2019 is mainly used for 1) Grape King Bio-Tech Research Institute, and 2) various upgrade and new production lines projects.





Appendix: Industry Trends

Confidential


Taiwan health food industry

Taiwan's health food industry is growing


Taiwan health food industry continues to be driven by consumers' increasing interest in healthier lifestyles as a cost-effective way to combat ageing and prevent modern illness.



We have been gaining market share in Taiwan's health food industry and we are also the industry leader in both mushroom-based supplements and probiotics.



Grape King's market share in Taiwan health food industry




48

Taiwan direct selling industry

Health food takes up ~60% of direct selling industry in Taiwan

According to Taiwan FTC, health food takes up 60% of the direct selling market share, which shows that direct selling is an important channel for health food products.



Taiwan direct selling industry is strictly regulated with entry barrier



Sales incentive system

- 1) Reasonable product price (mark-up on pricing);
- 2) Reasonable compensation structure (distribution of profit)

Member's system

According to Taiwan's regulation, it is illegal to produce earnings by simply introducing new participants instead of engaging in promotion & selling goods or services. Companies in violation may be subject to imprisonment and/or fines.

Pro-Partner is the only domestic direct selling company in Top 10

Top 10 players have high market concentration Pro-Partner has highest sales per product among top 3 players




China health food industry

China's health food industry grew 21% CAGR between 2011-2018

China's health food industry mainly driven by economic growth, disposable income, and rising health awareness. The industry has been growing for the past 7 years.

China direct selling has significant growth from 2011-2018

Direct selling has become an important distribution channel as sales from direct selling has grown from 26% in 2011 to 47% in 2018.








Despite the latest Administrative Measure of Health Food Registration and Filing having streamlined the certification process for vitamins and minerals, other products still need to go through the "Blue Hat" certification process by the CFDA.

China health food industry

Global probiotics market is still growing

According to Statista, global probiotics market has reached US\$40 bn with Asia Pacific region being the largest of all. The market is still increasing and is estimated to grow 7.0% CAGR between 2016-2022.



Grape King is the 7th largest distributor globally

We are ranked as the 7th largest probiotics supplement company globally, this also makes us the largest player in Greater China. Grape King is known for its capability in developing different strains of probiotics that target different health benefits.




China probiotics market

China probiotics market is expected to reach Rmb 85 bn in 2020

China's probiotic consumption remains at a relatively early stage and the supply is mostly dependent on import. According to ASKCI, China probiotics market is forecasted to reach RMB 85 bn dollars by 2020.

Taiwan and China probiotic supplement market are expected

According to Euromonitor, both Taiwan and China's probiotic supplement market are expected to deliver 27% and 23% of growth in 2016-2021, respectively.



Probiotics Supplements Retail Value (2016-2021)

